# ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

Study · id `cardio:ct-nct03462498` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03462498](<https://clinicaltrials.gov/study/NCT03462498>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03462498

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 3008 participants.

## Technical summary

Registry record NCT03462498. Randomized; no masking; primary purpose prevention. Start 2018-04-02 (actual); primary completion 2021-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 3008 participants (enrolled count; ClinicalTrials.gov record NCT03462498, source copy `cardio:ctgov-nct03462498-2024-06-14`, retrieved 2026-10-26)
- Started: 2018-04-02 (actual) (ClinicalTrials.gov record NCT03462498, source copy `cardio:ctgov-nct03462498-2024-06-14`, retrieved 2026-10-26)
- Primary completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT03462498, source copy `cardio:ctgov-nct03462498-2024-06-14`, retrieved 2026-10-26)
- Completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT03462498, source copy `cardio:ctgov-nct03462498-2024-06-14`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03462498, source copy `cardio:ctgov-nct03462498-2024-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03462498-2024-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
- Acronym: STOPDAPT-2 ACS
- Condition: Acute Coronary Syndrome
- Condition: Acute Myocardial Infarction
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Condition: Platelet Aggregation Inhibitors
- Intervention (Drug): 1-months DAPT
- Intervention (Drug): 12-month DAPT
- Lead sponsor: Kyoto University, Graduate School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Kyoto University, Graduate School of Medicine (`cardio:org-kyoto-university-graduate-school-of-medicine`)

## Provenance

Content hash: daad7cdd241ee9e5d0dc68f9eb22fc9dc0bdf448b475caf88afd8f9a385477fe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
